Clinical Trial Update: Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of Bevasiranib and Lucentis for wet age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Bevasiranib
• Lucentis (ranibizumab)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Age Related Macular Degeneration | Phase 3 | Status: WITHDRAWN